EANM Annual Congress 2025

PLANET^®  Onco Dose v3.2

Multi-radionuclide, multi-workflow, multi-therapy enabling voxel-based personalized dosimetry for SIRT & MRT

DOSIsoft Booth #104

Now available for clinical use across Europe, the latest release of  PLANET^® Onco Dose v3.2 is an “All-in-one” dosimetry solution dedicated to patient-specific Theranostics. The novel PLANET^® platform is specially designed to integrate multi-radionuclide approaches, implement multi-workflow solutions, and support multi-therapy applications. Clinically validated, its product features — spanning patient diagnostics, treatment planning, and disease follow-up— enable highly personalized treatment for each patient.

Multi-radionuclide: Already supporting ⁹⁰Y resin & glass microspheres and ¹⁷⁷Lu, the solution now includes two additional radionuclides, ¹⁶⁶Ho and ¹³¹I, with the flexibility to integrate further beta- and gamma-emitting isotopes under the same certification.

Multi-workflow: Designed to seamlessly integrate into existing clinical workflows, PLANET^®  Onco Dose supports both SIRT (Selective Internal Radiation Therapy) and MRT (Molecular Radiation Therapy) dosimetry, covering full 3D and 2D/3D hybrid methods for multi-time point workflows, as well as the newly introduced single-time point workflow – using a single imaging acquisition to improve workflow efficiency.

Multi-therapy: The platform is suited for a variety of treatments, including ¹⁷⁷Lu-PSMA (prostate-specific membrane antigen) therapy, ¹⁷⁷Lu-PRRT (peptide receptor radionuclide therapy) for neuroendocrine tumors, ⁹⁰Y or ¹⁶⁶Ho radioembolization, ¹³¹I-mIBG for neuroblastoma, radioiodine treatment for hyperthyroidism and thyroid cancer, and more.